Luciano Adorini

Vertex Pharmaceuticals (United States)

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Laura Giuseppina Di Pasqua

University of Pavia

ITALY

View details

Andrea Ferrigno

Professore Associato di Farmacologia

Università degli Studi di Pavia

ITALY

View details

David Orlicky

Associate Professor

UNITED STATES

View details

Michael Trauner

Professor of Medicine and Chair of Gastroenterology and Hepatology

Medical University of Vienna

AUSTRIA

View details

Justine Gillard

EPFL (École Polytechnique Fédérale de Lausanne)

SWITZERLAND

View details

Stefano Perlini

University of Pavia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luciano Adorini

Research Interests

Explore related searches

Contact this professor

Articles (10)

Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis

Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment.

An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations

NASH therapies head toward landmark approval.

The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice

Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats

Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism

Altered ethanol metabolism and increased oxidative stress enhance alcohol-associated liver injury in farnesoid X receptor-deficient mice.

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Collaborators (6)

Laura Giuseppina Di Pasqua

Andrea Ferrigno

David Orlicky

Michael Trauner

Justine Gillard

Stefano Perlini

Make your next move.